BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., (“Imbria”), a clinical-stage company developing transformational cardiovascular disease therapeutics, today announced a ...
SOUTH SAN FRANCISCO, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of ...
MyoKardia Announces Positive Topline Data from its Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced topline data from MAVERICK-HCM, the company’s Phase 2 clinical trial of mavacamten in ...
Pivotal Phase 3 clinical trial is actively enrolling patients in 20 countries, with all sites expected to be operational by Q3 2025 THE WOODLANDS, Texas, May 19, 2025 (GLOBE NEWSWIRE) -- Lexicon ...
In the primary safety endpoint of the MAVERICK HCM trial, 10.3% of patients in the mavacamten group experienced one or more serious adverse events (AEs) versus 21.1% of placebo patients, reported ...
– Topline Phase 2 data from the IMPROVE-ISCHEMIA clinical trial in Stable Angina also anticipated in 4Q 2023 – BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, ...
ACACIA-HCM is a Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effect of aficamten compared to placebo on health-related quality of life in ...
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the dosing of the first patient in the Phase 2 ...
Partnership further supports trial recruitment; FORTITUDE-HCM to be highlighted at upcoming HCMA Annual Patient Meeting Enrollment underway for the global, multicenter, double-blind Phase 2b trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback